Pharmaceutical

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases…

10 months ago

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors – – Company to…

10 months ago

Notice to the BBS-Bioactive Bone Substitutes Plc’s Extraordinary General Meeting

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 28 September 2023 at 2.20 pm (EET) Notice to the BBS-Bioactive Bone Substitutes Plc’s…

10 months ago

BioNTX Names Osteal Therapeutics 2023 Rising Star

President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award…

10 months ago

Renalytix Reports Full Year Fiscal 2023 Results

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled…

10 months ago

Matinas BioPharma to Present at Two Investment Conferences in October 2023

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining…

10 months ago

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based…

10 months ago

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in…

10 months ago

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe…

10 months ago

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023

CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…

10 months ago